Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 30.
doi: 10.1186/s12964-025-02605-1. Online ahead of print.

The NewroBus platform: engineered humanized anti-TfR1 nanobodies for efficient brain delivery

Tao Yin #  1 , Metin Yesiltepe #  1 , Sanjay Metkar #  1 , Aubin Ramon  2 , Matthew Greenig  2 , Pietro Sormanni  2 , Luciano D'Adamio  3   4
Affiliations
Free article

The NewroBus platform: engineered humanized anti-TfR1 nanobodies for efficient brain delivery

Tao Yin et al. Cell Commun Signal. .
Free article

Abstract

Background: Delivery of biologic therapeutics to the central nervous system (CNS) is hindered by the blood-brain barrier (BBB), which restricts large molecule passage. Receptor-mediated transcytosis via transferrin receptor 1 (TfR1) provides a physiological route for selective BBB transport. This study aimed to develop human-specific nanobodies that engage TfR1 without disrupting transferrin function, enabling safe and efficient CNS delivery of therapeutic biologics.

Methods: Single-domain camelid antibodies targeting human TfR1 were isolated, humanized, and optimized through computational and artificial intelligence-guided algorithms to improve humanness, solubility, and stability. Binding kinetics were quantified by surface plasmon resonance using a 1:1 Langmuir model. In vivo BBB permeability and safety were assessed in rats genetically humanized for TfR1 and transferrin following intravenous or subcutaneous administration.

Results: Optimized TfR1-binding nanobodies exhibited high affinity for human TfR1, with equilibrium dissociation constants (KD) in the picomolar range. These nanobodies crossed the BBB efficiently without interfering with transferrin binding or iron homeostasis and were therefore designated NewroBus. When fused to humanized tumor necrosis factor alpha (TNFα)-neutralizing nanobodies, NewroBus heterodimers maintained BBB permeability and achieved sustained cerebrospinal fluid and serum levels for at least three days after subcutaneous dosing. Chronic administration of representative constructs in humanized rats did not alter hematologic parameters, indicating absence of TfR1-related hematotoxicity.

Conclusions: Humanized TfR1 nanobodies (NewroBus) enable efficient, TfR1-dependent transcytosis of biologics across the BBB while preserving iron transport and safety. Their high binding affinity, favorable pharmacokinetic properties, and modular fusion capacity position NewroBus as a versatile platform for CNS delivery of therapeutic proteins.

Keywords: Alzheimer Disease; Blood–brain-barrier; Nanobody; Single-domain antibody; TNFα; TNFα inhibition.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: L.D. is the Founder of NanoNewron LLC, which has licensed from Rutgers University the intellectual property related to these molecules. L.D., T.Y., M.Y., and S.M. are inventors of the underlying technology. A.R., M.G., and P.S. served as paid consultants for NanoNewron LLC, performing AI- and machine-learning–based sequence analyses and suggesting mutagenesis strategies for nanobody optimization.

References

    1. Johnsen KB, Burkhart A, Thomsen LB, Andresen TL, Moos T. Targeting the transferrin receptor for brain drug delivery. Prog Neurobiol. 2019;181:101665. https://doi.org/10.1016/j.pneurobio.2019.101665.
    1. Pardridge WM, Buciak JL, Friden PM. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther. 1991;259:66–70.
    1. Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther. 2000;292:1048–52.
    1. Ullman JC, Arguello A, Getz JA, Bhalla A, Mahon CS, Wang J, et al. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci Transl Med. 2020. https://doi.org/10.1126/scitranslmed.aay1163.
    1. Weber F, Bohrmann B, Niewoehner J, Fischer JAA, Rueger P, Tiefenthaler G, et al. Brain shuttle antibody for Alzheimer’s disease with attenuated peripheral effector function due to an inverted binding mode. Cell Rep. 2018;22:149–62. https://doi.org/10.1016/j.celrep.2017.12.019.

LinkOut - more resources